Network Reconstruction Reveals that Valproic Acid Activates Neurogenic Transcriptional Programs in Adult Brain Following Traumatic Injury by Gerald A. Higgins et al.
RESEARCH PAPER
Network Reconstruction Reveals that Valproic Acid Activates
Neurogenic Transcriptional Programs in Adult Brain Following
Traumatic Injury
Gerald A. Higgins1 & Patrick Georgoff 2 & Vahagn Nikolian 2 & Ari Allyn-Feuer 1 & Brian Pauls 3 &
Richard Higgins4 & Brian D. Athey1,5 & Hasan E. Alam2
Received: 7 November 2016 /Accepted: 17 February 2017
# The Author(s) 2017. This article is published with open access at SpringerLink.com
ABSTRACT
Objectives To determine themechanism of action of valproic
acid (VPA) in the adult central nervous system (CNS) follow-
ing traumatic brain injury (TBI) and hemorrhagic shock (HS).
Methods Data were analyzed from different sources, includ-
ing experiments in a porcine model, data from postmortem
human brain, published studies, public and commercial
databases.
Results The transcriptional program in the CNS follow-
ing TBI, HS, and VPA treatment includes activation of
regulatory pathways that enhance neurogenesis and sup-
press gliogenesis. Genes which encode the transcription
factors (TFs) that specify neuronal cell fate, including
MEF2D, MYT1L, NEUROD1, PAX6 and TBR1, and their tar-
get genes, are induced by VPA. VPA represses genes re-
sponsible for oligodendrogenesis, maintenance of white
matter, T-cell activation, angiogenesis, and endothelial
cell proliferation, adhesion and chemotaxis. NEUROD1
has regulatory interactions with 38% of the genes regulat-
ed by VPA in a swine model of TBI and HS in adult
brain. Hi-C spatial mapping of a VPA pharmacogenomic
SNP in the GRIN2B gene shows it is part of a transcrip-
tional hub that contacts 12 genes that mediate chromatin-
mediated neurogenesis and neuroplasticity.
Conclusions Following TBI and HS, this study shows that
VPA administration acts in the adult brain through differen-
tial activation of TFs responsible for neurogenesis, genes re-
sponsible for neuroplasticity, and repression of TFs that spec-
ify oligodendrocyte cell fate, endothelial cell chemotaxis and
angiogenesis.
Short title: Mechanism of action of valproic acid in trau-
matic brain injury
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ChIP-seq ChIP-sequencing is a method used to analyze
protein interactions with DNA
eQTL Expression quantitative trait loci
GWAS Genomewide association studies
hQTL Histone quantitative trait locus
H3 Histone 3, one of the 5 main histone proteins
involved in the structure of the nucleosome in the
chromatin of eukaryotic cells
H3K9me2/
3
Histone H3 di- or tri-methylated at residue lysine
9. histone marks that are found in facultatively
repressed genes
H3K27ac Histone H3 acetylated at residue lysine 27.
H3K27ac is associated with the higher activation
of transcription and therefore defined as an ac-
tive mark of both enhancers and promoters
H3K27me2/
3
Histone H3 di- or tri-methylated at residue lysine
27. histone marks that are found in facultatively
repressed genes
H4 Histone 4, one of the 5 main histone proteins
involved in the structure of the nucleosome in the
chromatin of eukaryotic cells
HDAC Histone deacetylase
HOT High occupancy by transcription factors. indica-
tive of enhancers and promoters, especially in
developmentally important genes
HS Hemorrhagic shock
IC50 Concentration of an inhibitor where the response
(or binding) is reduced by half
TAD Topologically-associating domain, the basic spa-
tial unit of transcription in the human genome
TBI Traumatic brain injury
TF Transcription factor
SK-N-SH SK human caucasian neuroblastoma, an im-
mortalized human neuronal cell line
VPA Valproic acid
GENE SYMBOLS
ARID1A AT-rich interaction domain 1A
ASCL1 Achaete-Scute family BHLH transcription
factor 1
ATF7IP Activating transcription factor 7 interacting
protein
BCL11A B-Cell CLL/Lymphoma 11A
BCL2L11 BCL2 like 11
BMP2 Bone morphogenetic protein 2
BTG2 BTG family member 2
CASP3 Caspase 3
CCDCC117 Coiled-coil domain containing 117
CCL2 Chemokine C-C Motif Ligand 2
CHAF1B Chromatin assembly factor 1 subunit B
CTCF CCCTC-binding factor
CYR61 Cysteine rich angiogenic inducer
ELK1 ELK1 ETS transcription factor
EPHB2 EPH receptor B2
EWSR1 EWS RNA binding protein 1
FGF7 Fibroblast growth factor 7
FGF9 Fibroblast growth factor 9
GRASP GRP1 (General receptor for
phosphoinositides 1)-associated scaffold
protein
GRIN2B Glutamate ionotropic receptor NMDA type
subunit 2B
IL1RN Interleukin 1 receptor antagonist
KREMEN1 Kringle Containing Transmembrane Protein
1
MEF2C Myocyte enhancer factor 2C
MEF2D Myocyte enhancer factor 2D
MYT1L Myelin transcription factor 1 Like
NEUROD1 Neuronal differentiation 1
NF1 Neurofibromin 1
NR1D1 Nuclear receptor subfamily 1 group D mem-
ber 1
NR4A1 Nuclear receptor subfamily 4 group A mem-
ber 1
NR6A1 Nuclear receptor subfamily 6 group A mem-
ber 1
OPALIN Oligodendrocytic Myelin Paranodal and
Inner Loop Protein
PAX6 Paired box 6
PMP2 Peripheral Myelin Protein 2
PPARD Peroxisome proliferator activated receptor
delta
PROX1 Prospero homeobox 1
PRRX1 Paired related homeobox 1
SETDB1 SET domain bifurcated 1
SIRT1 Sirtuin 1
SMARCB1 SWI/SNF related matrix associated, actin
dependent regulator of chromatin, subfamily
B, member 1
SOX10 SRY-box 10
ST18 Suppression of Tumorigenicity 18 zinc finger
TBR1 T-box brain 1
THBS1 Thrombospondin 1
XBP1 X-box binding protein 1
ZNRF3 Zinc and ring finger 3
INTRODUCTION
The mechanism of action of VPA as an anticonvulsant, mood
stabilizer and analgesic in the human central nervous system
(CNS) has not been adequately characterized. VPA and its
derivatives exhibit a variety of effects which are cell- and tis-
sue-specific, differ based on disease state, age, gender and
ethnicity, and may be effective or deleterious. VPA is a weak
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blocker of sodium and calcium ion channels, and may inhibit
key enzymes in the catabolism of gamma-aminobutyric acid
(GABA), including ABAT (4-aminobutyrate aminotransferase)
at physiologically relevant concentrations (1). There is also ev-
idence that VPA exerts its antiepileptic action through differen-
tial regulation of the GRIN2B (Glutamate Ionotropic Receptor
NMDA Type Subunit 2B) gene (2). VPA is an effective inhib-
itor of histone deacetylases (HDACs), with an IC50 (0.4 mM)
well within the therapeutic range of VPA (0.35–0.7 mM in
serum). VPA causes robust chromatin decondensation, with
potent acetylation of core histones such as H3 andH4 that leads
to activation of development gene expression (3,4). VPA has
been shown to be neuroprotective in animal models of traumat-
ic brain injury (TBI) (5,6), spinal cord injury (7), and in neuro-
degenerative disease (8). In a swine model of TBI and hemor-
rhagic shock (HS) VPA decreases brain lesion size, improves
neurologic recovery, and down-regulates genes associated with
necrosis, apoptosis, and inflammation (9). The HDAC inhibi-
tor, sodium butyrate, with a mechanism of action like that of
VPA, has been shown to activate neurogenesis in rodent brain
following ischemic injury (10). These results suggest different
ways in which VPA may act in parallel to provide benefit in
epilepsy, mood disorders, migraine, as well as recovery follow-
ing trauma.
It appears that VPA-induced histone acetylation is not suf-
ficient for chromatin decondensation, but rather a down-
stream effect of HDAC inhibition, suggesting that the drug
suppresses the expression of proteins involved in maintenance
of heterochromatin and/or uses chromatin remodeling pro-
teins as intermediaries (11–13). It is also routinely used to
remove histone methylation in cellular domains such as the
lamina-associating domain (LAD) located just interior of the
nuclear membrane, a region containing heterochromatin, in
which exposure to VPA abolishes H3K27 and H3K9 meth-
ylation (14).
Recent studies of the epigenomic control of gene expres-
sion that has identified distinct mechanisms through which
chromatin interactions mediate transcriptional programs in-
volving topologically-associating domains (TADs), enhancer-
promoter loops and actively transcribed regions of the human
genome characterized by the histone mark H3K27ac (15–17).
It has been shown that SNPs which disrupt the boundaries of
TADs cause serious health problems (18).; and causal SNPs
exhibit significant allele bias in open chromatin (19). In addi-
tion, the greater the number of spatial connections a given
enhancer or promoter maintains genomewide indicates both
the potency of the regulatory element and its validity (20),
especially for CNS genes that are involved in coordinated
transcriptional programs of neurogenesis and neuroplasticity
(20).
Our hypothesis is that VPA acts through transcriptional
activation and repression of specific genes resulting in
chromatin-mediated neurogenesis and neuroplasticity in the
adult CNS and inhibition of glial scarring. To determine the
validity of this premise, we analyzed experimental and public
data. We then reconstructed a gene regulatory network that
mediates VPA’s mechanism of action in human brain, and
found that the drug exerts widespread effects in adult brain
including a transcriptional program of neurogenesis and
neuroplasticity, involving TFs that have been shown to pro-




Figure 1 shows an overview of the experimental design. Public
databases and sources used in this analysis are specified in
Supplementary Table 1. These included experimental results
from a swine model of TBI and hemorrhage (5,9). Other
primary data included microarray expression data from post-
mortem human brain tissue obtained from the Human Brain
Atlas of the Allen Brain Science Institute (21) and other
sources (22).
Experimental data from an animalmodel of TBI and HS
Examination of gene expression data from a swine model of
TBI and Hemorrhagic Shock exhibited functional recovery
following VPA therapy showed remarkable enrichment of
transcription factors (TFs) that were regulated in a significant
manner by the drug. In the animal model, swine were sub-
jected to controlled TBI and hemorrhage (40% blood vol-
ume), kept in shock for 2 h, and resuscitated with vehicle or
vehicle + VPA (n= 3 per group). The vehicle was Hextend
(Hospira Inc. Lake Forest, IL) at 50 mL/min versus (2)
Hextend at 50 mL/min plus VPA at 300 mg/kg (EMD
Biosciences Inc., La Jolla, CA). In the Hextend +VPA group,
VPA treatment was started 1 h after hemorrhage at an infu-
sion rate of 100 mg/kg per hour intravenously. The vehicle
and treatment groups received identical volumes of fluid,
which matched the volume of shed blood. After 6 h, brain
RNA was isolated, and gene expression profiles were mea-
sured using a Porcine Gene ST 1.1 microarray (Affymetrix,
Santa Clara, CA).
Gene expression data from postmortem human brain
Results of microarray expression analysis from postmortem
human brain were obtained from different sources (21,22).
In a patient cohort with epilepsy, patients on VPA therapy
were compared to controls at time of death (TOD) for relative
levels of several TFs, nuclear receptors, and other mRNAs
(23). Sample sizes for each group were N = 6 for epileptic
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patients on VPA therapy at TOD, N= 6 for epileptic patients
on a different anti-convulsant drug at TOD.
Experimental data from the human SK-N-SH cell line
Publicly available date from SK-N-SH cells were used for two
applications: (1) For determination of DNAse I hypersensivity
and allele bias, as they are included as examples in the
deltaSVM machine learning algorithm (19), and (2)
Evaluation of spatial interactions in the human genome using
data from a high resolution Hi-C dataset (19). To discover
how the VPA pharmacogenomic SNPs we selected produced
robust pharmacogenomic stratification, evaluation of the
chromatin interactions of regulatory elements they were locat-
ed in was used to preliminarily map the putative VPA phar-
macodynamic pathway in human brain.
SK-N-SH cells are a human neuroblastoma cell line
which > contains a mixture of at least 2 cell types.
Published literature on pharmacogenomic associations
and VPA targets and pathways
Two hundred and fifty-four peer-reviewed published articles
were retrieved between January 1 and October 1 2016, in-
cluding gene association studies, as well as basic and clinical
pharmacology reports. An automated Boolean search string
was used in PubMed (24), Google Scholar (23) and
clinicaltrials.gov (25), consisting of Bvalproate OR valproic
acid OR sodium valproate OR divalproex sodium AND
pharmacodynamics OR mechanism of action OR brain OR
pathways AND pharmacogenomic AND bipolar disorder
AND epilepsy AND migraine headache AND gene OR
Fig. 1 Overview of the
experimental design used in this
study. (1) Shows steps to annotate
putative VPA pharmacogenomics




methods. In (1) numbers refer to
the different annotation steps of the
bioinformatics pipeline. Details can
be found in the text and in
Supplement.
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SNP AND association AND human.^There are no published
genomewide association studies (GWAS) that are focused on
medication response or adverse events related to only valproic
acid therapy in epilepsy, bipolar disorder or migraine. There
are however, several GWAS that have investigated SNPs as-
sociated with human populations that have treatment-
resistant or refractory epilepsy. These studies are made up
primarily of patients who do not respond to a combination
of anticonvulsant drugs or worsen on therapeutic regimens.
Due to confounding related to polypharmacy these studies
were excluded. For this study, we avoided anything but pri-
mary research studies in which we re-tested all the parameters
and statistical tests that were employed. This dramatically
reduced the number of studies from 254 to 52 that could be
included in this analysis.
Analysis
VPA pharmacogenomic SNPs
To better understand humanCNS pathways that are involved
in the mechanism of action of valproic acid, we combined
SNP imputation with bioinformatics analysis as performed
in a previous study (22). SNPs included in the analysis were
those likely to be associated with known biological targets of
VPA, could be functionally annotated, and were derived from
primary research studies. For this analysis of potential phar-
macodynamic pathways, we excluded pharmacokinetic genes
and their variants such as theUGT andCYP super-families. To
select VPA pharmacogenomic SNPs we combined SNP im-
putation from VPA pharmacogenomic association studies,
and performed computational and bioinformatics analysis as
descr ibed in detai l (22) . DrugBank (25) and the
pharmacogenomic mutation database (PGMD®; Qiagen)
lists pharmacodynamic targets that have been associated with
VPA (26), and these were also interrogated to gather addition-
al information.
In Fig. 1.1, bioinformatics analysis was used to identify the
most probable causal SNP from the association regardless of
the lead SNP(s) that were reported, and included the following
bioinformatics analysis to determine the functionality of the
variant (22): (1) Location in open chromatin as indicated by
peaks of DNAse I hypersensitivity, (2) Low to moderate meth-
ylation of any cytosine residues, (3) The presence of histone
marks that indicate regulatory function (H3K27ac +
H3K4me1 = enhancer; H3K27ac +H3K4me3 = promoter),
(3) The location of the variant within the context of the gene
or in an intergenic domain, (4) Whether the regulatory ele-
ment has yet to be annotated as a molecular quantitative trait
locus (eQTL, hQTL, etcetera), (4) Proteins, including tran-
scription factors, bound to the regulatory element as deter-
mined by ChIP-Seq indicating its regulatory function, (5)
Disruption by the pharmacogenomic SNP of transcription
factor binding sites as indicated by alterations in the position
weight matrix, (6) Association of the regulatory element with
the requisite RNA species (e.g., bi-directional enhancer
RNA = enhancer; mRNA= promoter), (7) Connectivity of
the regulatory element with other elements in the genome as
indicated by the Hi-C chromatin conformation capture meth-
od limited to SK-N-SH cells, which are the ENCODE Tier
2.5 neural surrogate cell line, (8) Transcriptional program-
ming by factors which are responsible for determination of
neuronal cell fate, (9) Determination of the allele bias of the
allelic variant using the deltaSVM algorithm (19), (10) exam-
ination of the neuroanatomical distribution of target gene ex-
pression data in postmortem human brain using both micro-
array and in situ hybridization data from the Human Brain
Atlas of the Allen Brain Science Institute (21).
Harmonization of nomenclature: pig, human and rodent genes
and their regulatory elements
This study involves cross-species comparisons from pig (Sus
scrofa), rat (Rattus norvegicus) and human (Homo sapiens). To en-
sure that we could reliably use inter-species nomenclature in
the context of the human CNS, we compared gene, promoter
and enhancer data using 3 resources: (1) comparative assess-
ment of pig, rodent and human transcriptomes for identity
(27), (2) thorough analysis of human accelerated regions in
human brain that are not present in other mammalian brains
for exclusion (28), (3) cross-species assessment of histone mod-
ifications, open chromatin and deep learning methods applied
to pigs, mice, rats and humans to ensure concordance of
identifiable enhancers, promoters, super-enhancers and
master TFs (29), and (4) enhancer-promoter loop conser-
vation across species using context‐dependent conserva-
tion (30). All gene symbols and homologous regulatory
elements were found to be the same, at least in regards
to nomenclature, chromatin state annotation, and relative
position within the genome. We then harmonized our
nomenclature with the results of the roadmap epigenome
mapping consortium. Thus, gene and protein symbols and
definitions were consistent with HGNC nomenclature, ex-
cept as indicated by citation in the text. Gene symbols are
from GENCODE except where indicated, and genomic
location coordinates are from build 38 of the Human
Genome.
For annotation, we focused on active enhancers, promoters
and transcription start sites, so other chromatin states were not
used in the present study, including flanking and poised regu-
latory elements, transcribed domains or repressed elements.
Although potential regulatory variants may be repressed in
one tissue or brain region but not another, we could directly
assess function in any biological system in this study, so we
relied on the data provided by the association studies.
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VPA-regulated transcription factors (TFs)
Next, we examined data on TFs, including master TFs as
defined by super-enhancer regulation in human brain that
are regulated by VPA, and TFs and genes that are targets of
these Master TFs (see Table I for the complete list of data
sources). We examined previously characterized transcrip-
tional networks that contained VPA-responsive TFs, results
on conserved network topology from model systems,
organisms and mechanisms of neurogenesis (34,35) and
known gene regulatory network dynamics (36–38). We also
looked at the overlap of VPA genes which encode TFs and
HOT (high-occupancy target) regions, which are bound by
large number of transcription factors (39). Other data sources
are detailed in Supplementary Table 1.
Chromatin remodeling proteins and complexes
Several and chromatin remodelers, including ARID1A,
BCL11A, CHAF1B, were among genes regulated by VPA.
We determined the regulatory targets of these genomewide,
and determined and to what degree they overlapped the
VPA-responsive promoters as part of the reconstruction of
the network. We also examined pioneer factors such as
PAX6, which appears to act in concert with chromatin re-
modeling complexes during neurogenesis, including published
data on TFs that are pioneer factors and chromatin state
regulators (Supplementary Table 1).
Reconstruction of VPA gene regulatory networks in the human
CNS
Figure 1.2 shows the method by which we reconstructed the
central VPA pathway in the human CNS. It involved:
Identification of databases relevant to modeling the VPA reg-
ulatory circuit, Data aggregation from public databases and
in-house data, manual curation of the data in the context of a
VPA central mechanism of action, preparation of curated
data for model integration, iterative gene set enrichment
analysis (GSEA) using different public and commercial soft-
ware, and pathway analysis using IPA® and the STRING
database of protein-protein interactions (40), as well as net-
work analysis using weighted gene co-expression network
analysis (WGCNA) in R (41) and node-edge modeling systems
modeling using Python (42). In addition to applying redun-
dant software analysis tools, we also used different open source
and commercial databases, including IPA® (43), Pathway
Commons (44) and Reactome (45) databases as well as man-
ual curation of the scientific literature, to determine network
interactions.
For reconstruction of VPA’s gene CNS regulatory path-
way, we used a hybrid model development method that com-
bines GSEA and pathway analysis/network modeling soft-
ware used in bioinformatics with a technique for constructing
core regulatory circuitry which includes super-enhancers, TFs
and auto-regulation, based on defined biological attributes of
transcriptional regulation in the human CNS (Supplementary
Table 1). During the project, we discovered several other TFs
that are regulated by VPA that directs cell fate, in addition to
many genes whose was expression was regulated by ASCL1
(Achaete-Scute Family BHLH Transcription Factor 1),
NEUROD1 (Neuronal Differentiation 1), MEF2C (Myocyte
Enhancer Factor 2C), MEF2D (Myocyte Enhancer Factor
2D), MYT1L (Myelin Transcription Factor 1 Like), and
TBR1 (T-Box, Brain 1). Many TFs were tightly coupled in
terms of target promoters, many of which were also involved
in neurogenesis and neuroplasticity. As such, this convoluted
super-program was investigated in greater detailed.
Relationship between VPA-regulated TFs and other TFs in human
brain and cell types
To understand the relationship between genes whose expres-
sion is highly regulated by VPA following brain injury in the
CNS, we first examined sets of TFs which were known to be
differentially regulated by VPA in brain and whose function
was linked to neurogenesis and suppression of gliogenesis in
human brain. Comparisons were made between VPA-
Table I Selected Pharmacogenomic Variants Selected for Allelic Variation in VPA Dose, Response and Pharmacodynamics in Human Populations. Noncoding
SNPs that Identified Regulatory Elements, Including Enhancers and Promoters
SNP GENEa TYPE deltaSVM
SCOREb
DISEASE EFFECT EFFECT SIZE REF
rs2857654_A CCL2 Enhancer −2.275704 Epilepsy Response in children 1.45 (1.06–1.99) (31)
rs3764028_G GRIN2B Promoter −5.097029 Epilepsy Dose range 1.7553 (1.219–2.291) (32)
rs2269577_G XBP1 Promoter 4.710044 BPD Responsec 1.2754 (0.329–2.221) (33)
a RefSeq nomenclature
b deltaSVM is a machine learning algorithm that determines the causal nature of gene variants, including DNAse I hypersensitivity and allele bias (21)
c Total treatment response score, Kruskal–Wallis test for valproate prophylactic treatment response. BPD: Bipolar disorder, sample containing patients with BPD 1
and BPD 2. Effect sizes generated using Cohen’s D-test adjusted for sample size
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responsive master TFs and their targets and other TFs in the
human telencephalon, and the different sets are represented
on a coronal section of the human telencephalon (Fig. 4).
Adult human brain regions, examined in the roadmap epige-
nome mapping consortium (15), included the angular gyrus,
anterior caudate, cingulate gyrus, hippocampal formation, in-
ferior temporal lobe and mid-frontal lobe. Cell types included
astrocytes and HUVEC, the latter a lymphoblastoid cell line
derived from human vascular endothelial cells.
TFs were assigned using a subset of ENCODE brain re-
gions and in astrocytes based on annotation of super-enhancer
status using histone marks such as H3K27ac and other char-
acteristics (15,17). From this analysis, only 8 of the TFs and
nuclear receptors regulated by VPA exhibit enhancer-like at-
tributes in various brain regions. Other enriched TFs include
NFIX, regulated by CHAF1B and SOX2. The correlation
between VPA-TFs and TFs which funct ion with
superenhancer status in different human brain regions is ob-
vious, with this small subset accounting for 31–48% of all TFs
across the telencephalon. In astrocytes, as shown in Fig. 4,
although only MEF2D is represented as a VPA-TF, 17% of
all TFs in this cell type are regulated by VPA-TFs. HUVEC
cells were used as a surrogate for CNS endothelial cells, and
MEF2C, MEF2D and NR1D1 are VPA-TFs, with these TFs
and their targets accounting for 18% of the TFs in this
lymphoblastoid cell line
RESULTS
VPA regulation of gene expression following injury
to the brain in a swine model
Most the genes differentially-regulated by VPA were several
master TFs that are highly expressed during development of
the CNS, and are also found in the developing adult human
telencephalon. TFs that target the greatest number of
differentially expressed genes were NEUROD1, ASCL1,
MEF2C, MEF2D, BCL2L11 (BCL2 Like 11), ELK1
(ELK1, ETS Transcription Factor), MYT1L, PPARD
(Peroxisome Proliferator Activated Receptor Delta), SIRT1
(Sirtuin 1), SMARCB1 (SWI/SNF Related, Matrix
Associated, Actin Dependent Regulator Of Chromatin,
Subfamily B, Member 1), and TF (Transferrin). All of these
genes except for SMARCB1, which is induced by VPA, were
found in the VPA-regulated set.
Analysis of significantly up- or –down-regulated genes
in the porcine model of TBI and HS showed that
NEUROD1 was involved in the regulation of 63% of
the regulated genes in this dataset. Using Fisher’s exact
test, the p-value of NEURDO1-regulated genes in the
dataset versus genes with those not known to be regulated
by NEUROD1 is p = 1.6E-05. Figure 2 shows the distribu-
tion of non-overlapping NEUROD1 interactions in this
dataset. The most common target of overlapping TFs
was CASP3 (Caspase 3), which is the target of 8 different
TFs, and SIRT1, PPARD and TBR1, all targeted by 5
different TFs. Common target TFs and nuclear receptors
involved in development and neuronal programming in-
cluded the up-regulated genes NR6A1 (Nuclear Receptor
Subfamily 6 Group A Member 1; 1.75 log2-fold), BCL11A
(B-Cell CLL/Lymphoma 11A; 1.6 log2-fold), MYT1L
(Myelin Transcription Factor 1 Like; 1.6 log2-fold),
TBR1 (1.49 log2-fold), NR1D1 (Nuclear Receptor
Subfamily 1 Group D Member 1, 1.42 log2-fold) and
MEF2C (1.42 log2-fold). Among VPA-responsive genes
that were up-regulated, there was also significant repre-
sentation of thyroxine-responsive genes, neurotransmitter
genes including corticotrophin releasing hormone, and
genes which encode proteins involved in neuronal cell
adhesion, synaptogenesis, axonal growth, dendritic arbor-
ization and the cytoskeleton. For additional information
about programmers of cell fate regulated by VPA follow-
ing CNS injury, please refer to the Supplement.
Fig. 2 Types of NEUROD1
control of genes differentially
regulated by VPA in adult swine
brain following injury. The 11
enhancers that control NEUROD1
include genes that are co-regulated
by the same enhancer as
NEUROD1 and genes which
harbor single gene variants that
impact enhancers that affect
NEUROD1 gene expression. For
details see Supplemental dataset.
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TFs that program oligodendrocytic cell fate, endothelial
cell fate and angiogenesis were significantly down-regulated
compared to other TFs in this dataset (p= 2.78E-04; Fisher’s
exact test). These included FGF7 (Fibroblast Growth Factor 7;
−3.2 log2-fold), PROX1 (Prospero Homeobox 1; −1.81 log2-
fold), SOX10 (SRY-Box 10; −1.81 log2-fold), PRRX1 (Paired
Related Homeobox 1; BMP2 (Bone Morphogenetic Protein
2; −1.73 log2-fold) and ST18 (Suppression Of Tumorigenicity
18, Zinc Finger; −1.22 log2-fold). Other significantly down-
regulated genes included CYR61 (Cysteine Rich Angiogenic
Inducer), OPALIN (Oligodendrocytic Myelin Paranodal And
Inner Loop Protein), PMP2 (Peripheral Myelin Protein 2) and
THBS1 (Thrombospondin 1).
Supplementary Figure 3 shows the significant functions of
the 50 most up-regulated and most down-regulated genes
following VPA therapy in a swine model of TBI and hemor-
rhage. These results show that in an animal model of TBI and
hemorrhage, VPA therapy induces genes associated with
neurogenesis and neuroplasticity, and represses those associ-
ated with cell loss, endothelial cell invasion, and angiogenesis.
Selection of VPA pharmacogenomic SNPs for further
examination
Table I shows VPA pharmacogenomic SNPs that were select-
ed for further analysis. These SNPs stratify response to VPA in
human populations, and all 3 are located in regulatory do-
mains (promoters or enhancers), and exhibit significant chro-
matin allele bias as measured by the deltaSVM algorithm (19).
They include:
1. The intronic SNP rs2857654_A located within the CCL2
gene, which encodes the Chemokine C-CMotif Ligand 2,
and is most significantly associated with cell movement
and migration of cells and this enhancer interacts with
VPA (31);
2. The 5′ SNP rs3764028_G located in the distal GRIN2B
promoter (32). Spatial mapping in SK-N-SH cells shows
that it forms an inter-chromosomal transcriptional hub
(Fig. 3a), contacting genes in cis- and trans- in SK-N-SH
cells that are enriched for genes involved in neuronal dif-
ferentiation and development of the CNS (Fig. 3a);
3. The 5′ SNP rs2269577_G located in the promoter of the
XBP1 (X-Box Binding Protein 1) gene (33), which functions
as a transcription factor during endoplasmic reticulum
(ER) stress by regulating the unfolded protein response.
Required for cardiac myogenesis and hepatogenesis during
embryonic development, and the development of secretory
tissues such as exocrine pancreas and salivary gland. An
enhancer co-regulates XBP1, EWSR1 (EWS RNA
Binding Protein 1), CCDCC117 (Coiled-Coil Domain
Containing 117), KREMEN1 (Kringle Containing
Transmembrane Protein 1) and ZNRF3 (Zinc And Ring
Finger 3) genes, which are co-localized within a TAD lo-
cated on chromosome 22 (46). The location of this SNP 5′
to the XBP1 gene is shown in Fig. 3b.
Fig. 3 Spatial context of promoters containing VPA pharmacogenomic SNPs. (a)Whole genome plot of transcriptional hub based on cis- and trans-contacts of
the SNP rs3764028_G in the promoter of the GRIN2B gene based on data fromHi-Cmapping of this SNP in the human neuronal cell line SK-N-SH. (b) Relative
location of the VPA pharmacogenomic SNP rs2269577 (green line), with histone marks H3K27ac and H3K4me4 indicative of an active promoter, location in a
DNase I hypersensitivity region indicative of open chromatin, and overlapping a HOT domain containing many TFs (39). This SNP is located within a TAD located
on chromosome 22 (26,600,000–28,000,000) (46) containing theXBP1 gene as well as other genes. Inset. Screenshots from the UCSC genome browser, build
hg18, taken from the UCSC genome browser in (b) (47).
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VPA modulates a transcriptional hub consisting of 12
genes in spatial contact with the GRIN2B promoter
The 5′ SNP rs3764028_G located in the distal GRIN2B pro-
moter is in a region associated with massive chromatin reor-
ganization in brain (48,49) in rodents and human cell lines.
This SNP detects a promoter that maintains spatial contact, as
determined by Hi-C maps of SK-N-SH cells. SK-N-SH cells
are a lymphoblastoid cell line which contains a mixture of 2
cell types. This regulatory community also contains 3 known
enhancers including 2 super enhancers as well as a promoter
with spatial contacts to genes associated with neuronal survival
and plasticity. This replicates a result from a study in mouse
brain in which researchers combined genome-wide analysis of
data sets for chromatin accessibility (FAIRE-Seq) and the en-
hancer mark H3K27ac, in which they found a subset of genes
associated with neuroprotection and plasticity that increased
transcription in adult mouse brain following activation of the
glutamate receptor (49). In our study, both gene set enrich-
ment using Gene Ontology, as well as manual inspection of
genes that maintain spatial contacts with the promoters and
enhancers detected by our putative causal SNPs demonstrate
selectivity for neuroplasticity and chromatin reorganization.
In agreement with their findings, genes whose abundance in-
creased included NR4A1, which regulates dendritic spindle
density and organization in human brain following neuronal
excitation, BTG2, a transcription factor that inhibits neural
precursor cell proliferation and stimulates neuron cell differ-
entiation and acts in histone arginine methylation, ILRN,
which is also in contact with an enhancer associated with
SNP rs2857654_A, and NF1, which differentially controls
neural stem cell proliferation. In addition, we identified con-
tacts with GRASP, part of a receptor complex scaffold that
regulates G protein-coupled glutamate receptor signaling,
MEF2D, which is regulated by NEUROD1, and EPHB2
(EPH Receptor B2), a developmentally-regulated receptor ty-
rosine kinase that functions in axonal guidance during devel-
opment. This promoter also maintains long distance spatial
contact with SETDB1, an H3-K9 histone methyltransferase
that regulates epigenetic gene silencing to maintain stem cell
pluripotency, a result that has been experimentally shown in
rodent brain and cell lines by other researchers (48,49).
The distal GRIN2B promoter maintains spatial interactions
with genes that program neuronal cell fate in humans, and are
highly responsive to VPA. These are TBR1 (T-Box, Brain 1),
which is up-regulated by VPA following TBI in our animal
model. TBR1 is a TF that acts as a potent programmer of
neurogenesis (50), controls the differentiation of pyramidal
cells in neocortex, and controls expression of theGRIN2B gene
in developing cerebral cortex (51). The other is FGF9
(Fibroblast Growth Factor 9), which is produced by develop-
ing neurons to maintain homeostasis within the surrounding
milieu. It plays an important role in the regulation of
embryonic development, cell proliferation, cell differentiation
and cell migration, regulation of gliosis during repair and
regeneration of brain tissue after damage and the differentia-
tion and survival of neuronal cells (52). Several of these genes
that exhibit spatial proximity to the GRIN2B promoter in hu-
man SK-N-SH cells are also up-regulated by VPA in the
swine model of TBI and hemorrhage. These include FGF9,
NR6A1, TBR1 and MEF2D.
Relationship between VPA-regulated TFs and other
TFs in human brain and cell types
To understand the relationship between genes whose expres-
sion is highly regulated by VPA following brain injury in the
CNS, we first examined sets of TFs which were known to be
differentially regulated by VPA in brain and whose function
was linked to neurogenesis and suppression of gliogenesis in
human brain. Comparisons were made between VPA-
responsive master TFs and their targets and other TFs in the
human telencephalon, and the different sets are represented
on a coronal section of the human telencephalon (Fig. 6).
Adult human brain regions included the angular gyrus, ante-
rior caudate, cingulate gyrus, hippocampal formation, inferior
temporal lobe and mid-frontal lobe. Cell types included astro-
cytes and HUVEC, the latter a lymphoblastoid cell line de-
rived from human vascular endothelial cells.
TFs were assigned using a subset of ENCODE brain
regions and in astrocytes based on annotation of super-
enhancer status using histone marks such as H3K27ac
and other characteristics. From this analysis, only 8 of
the TFs and nuclear receptors regulated by VPA exhibit
enhancer-like attributes in various brain regions. Other
enriched TFs include NFIX, regulated by CHAF1B and
SOX2. The correlation between VPA-TFs and TFs which
function with superenhancer status in different human
brain regions is significant (p = 3.12E-15), with this small
subset accounting for 31–48% of all TFs across the telen-
cephalon. In astrocytes, as shown in Fig. 4, although only
MEF2D is represented as a VPA-TF, 17% of all TFs
expressed in this cell type are regulated by VPA-TFs.
HUVEC cells were used as a surrogate for CNS endothe-
lial cells, and MEF2C, MEF2D and NR1D1 are VPA-
TFs, with these TFs and their targets accounting for
18% of the TFs in this lymphoblastoid cell line.
Examination of the interaction and correlation between
diverse datasets led to a definitive set of master TFs and their
target TFs that were involved in VPA-mediated neurogenesis.
Forty-seven TF targets of the 18 master transcription factors
regulated by VPA include are controlled by 18 master TFs
(Supplementary Table 2), but not all the master TFs are
expressed in the adult human telencephalon at high abun-
dance (Fig. 4). These data show that VPA-regulated TFs re-
sponsible for neuronal cell fate are found in the adult human
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brain, and TFs that can program fibroblasts into oligodendro-
cytes including OLIG2 and ST18, are also present. For details
concerning Fig. 4 see (53).
Next, we performed a GSEA on VPA-responsive versus
non-VPA TFs found in these different adult brain regions
and compared these results to those found in our animal mod-
el. Supplementary Figure 4 shows a comparison of gene set
enrichment, including brain region subsets from the data used
for Fig. 4, including (Supplementary Figure 4A), the set of
VPA-regulated TFs and (Supplementary Figure 4B) the set
of non VPA-responsive TFs. TFs found in human telenceph-
alon that are not VPA-responsive are not enriched for
neurogenesis, but are enriched for differentiation and devel-
opment of other cell types.
Preliminary evidence from microarray expression data
from postmortem human brain tissue
As part of a larger study examining patients with epilepsy, we
obtained limited data on TF gene expression on 6 patients
who were on VPA therapy at time of death (TOD) from the
Human Brain Atlas of the Allen Brain Science Institute (23).
These were compared to data from individuals who had no
known medication history. Figure 5 shows a comparison be-
tween individuals on VPA treatment at TOD versus controls.
As can be seen from this heatmap, patients on VPA had ele-
vated levels of TFs that are responsible for neuronal cell fate
specification, but reduced OLIG2 and ST18 gene expression,
which are involved in the specification of glial cell fate during
Fig. 4 Distribution of VPA-
regulated master TFs and their
target TFs in the VPA pathway
mapped onto a coronal section of
human brain. TFs in bold are VPA-
responsive master TFs, which are
regulated by super-enhancers
according to H3K27ac marks and
other attributes, based on
Supplementary Table 3 and (53).
Percentages indicate total number
of VPA-regulated TFs that have
been annotated as such in each
region.
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CNS development. Although MEF2C is involved in
neurogenesis and patterning of cortical structure, the heatmap
shows its expression appears to be slightly less in VPA patients
than in controls, especially in the amygdala. In contrast, the
abundance of BCL11A, CHAF1B, MEF2D, MYT1L,
NEUROD1, NR6A1, PPARD and TBR1 mRNA was signifi-
cantly higher in these brain regions than in epileptic patients
who were taking VPA at TOD than in control individuals
(p= 4.2E-07).
Sub-network analysis
Analysis of VPA gene expression from expression data from the
injured swine brain was made using several approaches, and
several important sub-networks are shown in Fig. 6.
Subsequently reconstruction of a network of the central VPA
pathway in human brain that extended the animal model in-
cluded genes that encode known TFs that direct cell fate in the
developing CNS in the human, a subset of nuclear receptors,
cytoskeletal proteins including NEFL, NEFH and INA, circa-
dian genes, genes whose products are associated with histone
acetylation, suppression of HDACs, apoptotic proteins, neuro-
transmitters including 15 potassium channels, corticotropin re-
leasing hormone, cholinergic receptors, GABA receptors, opi-
ate receptors, synaptic proteins, proteins that promoter neurite
extension, axonal growth and dendritic arborization, anti-
angiogenic proteins , growth factors and others .
Supplementary Figure 1 shows the reconstructed VPA gene
regulatory network of TFs in human brain as determined by
IPA® including master TFs, TFs, nuclear receptors, growth
factors, selected VPA pharmacogenomic genes and related
genes that are up- or down-regulated following TBA in an
Log2 heat map of mRNA abundance, normalized to standards (23).
Fig. 5 Differential regulation of TFs, nuclear receptor and chromatin remodeler involved in specification of cell fate in patients on VPA therapy at TOD versus
controls who had no recorded history of psychotropic medication at TOD. These data obtained from a study of patients with epilepsy, and medication-free
control individuals, showing samples from different regions of the telencephalon. Vertical stripes in each brain region indicates data from individual patients. AMY:
Amygdala; BG: Basal ganglia; CC: Cingulate cortex; HF: Hippocampal formation; FC: Frontal cortex; P: Parahippocampal gyrus; TC: Temporal cortex; S: Septum.
Courtesy, Allen Brain Science Institute (21).
Fig. 6 Examples of subnetworks in network reconstructed from injured
swine brain treated with VPA. These include 11% of the differentially-
regulated molecules in the dataset, enriched for TFs, nuclear receptors and
VPA pharmacogenomic genes (blue). Insets include a fraction of the genes
associated with the cytoskeleton and nucleoplasm, and the 17 functionally-
validated promoter targets of NEUROD1. Symbols in green indicate genes
up-regulated by VPA in this model and the red indicate down-regulated genes.
For extension of this network to the VPA pharmacodynamic pathway in hu-
man brain, see Supplementary Figure 1. In the entire dataset, the genes that
discretize VPA response include CCL2, with 23 direct interactions, GRIN2B,
with 20 direct interactions, and XBP1 with 4 direct interactions. Pathway
contacts made using the Bconnect^ function of IPA® (40). For symbol key,
see Supplementary Figure 1.
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animal model, as well as additional genes determined by IPA®
that are intimately associated with these genes in human brain
using the Bgrow^ function of the software. This forms the tran-
scriptional foundation of the central VPA pathway in human
brain. Although between 28 and 50% of VPA-inducible master
TFs are normally expressed in adult brain (Fig. 6) there are TF
genes that are not normally expressed at high abundance that
are responsible for activation of neurogenesis and suppression
of cell fate specification of non-neuronal cell types that are up-
regulated following VPA therapy. The STRING database (40)
leads to the same or a very similar network of TFs, as shown in
Supplementary Figure 2. Following reconstruction of the net-
work, we examined which drugs were most likely to impact this
pathway based on existing data. Analysis using the IPA®
Bupstream regulatory^ toxicology analysis, the most significant
drug/chemical regulating this network was VPA (p-value
2.98E-22 using Fisher’s exact test).
Supplementary Figure 1 only includes a fraction of the path-
way, including direct targets such as master TFs and some of
the genes they regulate, and represents a union of data from
human and a swine model of TBI and hemorrhage. Green
symbols show up-regulated genes following VPA treatment
versus vehicle in the swine model of TBA, and red symbols are
down-regulated genes following VPA treatment in the animal
mode l o f b ra in in ju ry . B lue symbo l s a re VPA
pharmacogenomic genes (Table I). Symbols lacking colors are
VPA-regulated genes that were predicted by IPA® using the
Bconnect^ function, as essential components of the same inter-
connected pathway expressed in human brain. We then com-
pared overlap of pathway components to previously defined
networks in the Reactome database (45), the IPA® database
(43) and Gene Ontology (54). Previously defined biological net-
works across tissues and species exhibited significant overlap
with the set of VPA pathway molecules. As might be expected
from the widespread action of VPA-responsive TFs that direct
neurogenesis, the 3 most significant overlaps were: (1) Neuronal
cell fate determination in mammals (p-value < 1.30E-13; q-val-
ue < 4.39E-10), (2) Nuclear receptor transcription pathway in
humans (p< 3.94E-13; q< 1.67E-10) and (3) Neurogenesis in
humans (p< 5.17E-12; q< 7.18E-10). Supplementary Table 2
shows a summary of the overlap of TFs found in this recon-
structed VPA gene regulatory network with a matrix of known
TFs responsible for: (1) CNS developmental processes, (2)
Specification of germinal layers of cerebral cortex, and (3)
Reprogramming/trans differentiation of different cell types to
neuroblasts, neural crest, neural progenitor cells and
neurotransmitter-specific neurons.
Many TFs in the VPA regulatory network are located
in HOTregions
It has been found that many master TFs regulated by super-
enhancers are also sites of high TF occupancy (HOT regions)
(39). HOT regions correlate with decreased nucleosome den-
sity and increased nucleosome turnover and are primarily
associated with open chromatin. Collectively, these HOT re-
gions span approximately 19% of the genome in other species
(39,55). Since the reconstructed VPA gene regulatory path-
way contains not only master TFs normally found in adult
brain (Fig. 4), and the drug induces numerous master TFs in
human brain that are expressed at high abundance during
CNS development, we examined the overlap between HOT
regions and genes in our pathway. Many genes in the recon-
structed VPA pathway were in HOT regions.
DISCUSSION
The rapid action of VPA in the adult brain appears to reduce
the impact of ensuing trauma following TBI and hemorrhage,
and mitigates neuronal atrophy in bipolar disorder and epi-
lepsy. This raises the question of whether newly differentiated
neurons are absorbed into active neuronal regulatory net-
works to become part of functional neurophysiological path-
ways. The highly significant changes related to neuroplasticity
that is observed in our animal model of TBI and hemorrhage
suggest this may be true. However, it is most probable that
VPA acts through different pathways following traumatic in-
jury than that observed in healthy tissue. Previous studies in
rodent models of ischemia followed by treatment with HDAC
inhibitors including VPA and sodium butyrate have observed
activation of neurogenesis in the adult brain (10,56), although
repair mechanisms may depend on the post-injury timeframe
(56).
Our results show that existing sources of disparate data can
be used to model transcriptional networks that are activated
by VPA in the human CNS. VPA generates widespread
changes in chromatin state in the genome accompanied by
targeted transcriptional changes that mediate neurogenesis
(12). Although VPA in combination with other small com-
pounds may be able to induce neurogenesis (57), previous
research suggests that it acts, in part, through TFs responsible
for determination of neuronal cell fate, such as NEUROD1
and TBR1 ((58): Supplementary Table 3). Specific chromatin
modifying protein complexes that include ARID1A are criti-
cal for chromatin remodeling during neurogenesis (59,60),
including acetylation of the histone mark H3K27, which de-
fines active enhancers and promoters. Based on these findings
we have devised a model that attempts to explain VPA’s
mechanism of action in the human adult brain (Fig. 7). This
model consists of 3 components: (1) Activation of
AKT1/mTOR signaling pathways by GABA receptors
and/or growth factors that activate genes whose expression
provides neuroprotection, (2) Opening of chromatin through
HDAC inhibition, leading to histone acetylation and wide-
spread gene expression including expression of genes involved
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in the cell cycle, and (3) Induction of chromatin state remod-
eling complexes such as npBAF containing proteins encoded
by ARID1A, BCL11A and CHAF1B, which act as interme-
diaries for pioneer TFs to initiate neurogenesis and repression
of non-neuronal gene expression. These mechanisms of action
are not mutual exclusive and occur concurrently with suppres-
sion of TFs such as ST18, which is responsible for glial cell fate
programming during development (63).
In cell lines, treatment with VPA causes rapid and exten-
sive chromatin decondensation, suggesting that VPA broadly
and directly acetylates histones for transformation of chroma-
tin state from heterochromatin to euchromatin. Thus, it may
be that VPA acts directly to inhibit histone deacetylases.
Alternatively, rapid activation of chromatin remodeling pro-
teins such as the ARID1A component of the neural
progenitors-specific chromatin remodeling complexes
npBAF and nBAF may mediate chromatin remodeling fol-
lowing administration of VPA. Ultimately, it may be that all
of these mechanisms contribute to VPA’s mechanism of action
in the human CNS.
Adequate data now exist to elucidate the transcriptional
program that resolves all of the components that are necessary
and sufficient to determine VPA’s mechanism in the human
brain using knowledge-based discovery. This capability has
been demonstrated in other domains, including modeling of
the core regulatory circuits in different human tissues and cell
lines, including super-enhancers, master TFs and TFs respon-
sible for specifying cell fate (Supplementary Tables 1, 3). In
this study, we identified important master TFs such as
NEUROD1 and TBR1 that are induced by VPA following
TBI in adult brain, but normally expressed at low levels in the
mature human telencephalon.
Preliminary data from postmortem human brain must be
considered preliminary, as complete medical histories are not
available on either patients or controls, there is heterogeneity in
the data, and this microarray expression reflects variability
Fig. 7 Putative mechanisms of VPA
in human brain. (1) Activation of
AKT1/mTOR signaling pathways by
GABA receptors and/or growth
factors that activate genes whose
expression provides
neuroprotection, (2) VPA acts
directly to open chromatin through
HDAC inhibition, leading to histone
acetylation and widespread gene
expression including expression of
genes involved in the cell cycle, and
(3) Chromatin state remodeling
complexes such as npBAF
containing proteins encoded by
ARID1A, BCL11A and CHAF1B,
act as intermediaries to prepare for
pioneer TFs to initiate neurogenesis
and repression of non-neuronal
gene expression. There is evidence
that PAX6 acts as a pioneer factor in
concert with BAF during
neurogenesis (61,62). These
mechanisms are not mutually
exclusive
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associated with a single time point in the analysis of postmortem
human brain tissue lacking cause of death in most cases. In
addition, although controls were selected based on lack of med-
ication history, medical history was not well characterized.
Since VPA relieves symptoms in disorders such as bipolar
disorder, which involves neuronal loss and neural atrophy (64),
it is tempting to speculate that VPA may have a positive effect
on a range of damaged brain tissue, from mild atrophy to the
critical damage that is often observed following TBI.
Conversely, VPA may generate aberrant hyperplasia of differ-
ent cell types in human brain as has been suggested (65). This
could account for rebound seizures and CNS impairment in-
cluding encephalopathy after chronic treatment with VPA (66).
Further investigation is warranted to completely under-
stand howVPA and other HDAC inhibitors can provide func-
tional recovery after severe trauma to the human brain and
spinal cord, and to a lesser extent, suppress epileptogenesis,
alleviate mania in bipolar disorder, and act as an analgesic in
migraine. Modeling using rich data resources as was per-
formed in the current study generate testable hypotheses for
more focused experiments in subsequent studies.
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